Dapagliflozin (DAPA) is a sodium-glucose linked transporter 2 (SGLT2) inhibitor used to lower blood sugar levels in patients diagnosed with type-2 diabetes mellitus (T2DM) 6. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.